2. American Heart Association Scientific Sessions

4. Importance of Targeting LDL-C

5. Trial Designs Compared Statins

6. Are Statins Enough?

7. Residual Risk Poorly Managed

8. PCSK9 Inhibitors

9. How Low is Too Low?

10. Please join us as we move on to the next interview.

16. PCSK9 Inhibitors Clinical Trials

17. Practicalities of PCSK9 Inhibitors

18. Few Clinical Barriers

19. PCSK9 Inhibitors Their Place in the Armamentarium

21. 2013 ACC/AHA Guidelines

22. Role of PCSK9 Inhibitor in Future Recommendation

24. Future Drug Therapy

25. Closing Thoughts

26. Abbreviations

27. References

28. References (cont)

29. References (cont)